[go: up one dir, main page]

ME02515B - Protutijela protiv bmp-6 - Google Patents

Protutijela protiv bmp-6

Info

Publication number
ME02515B
ME02515B MEP-2016-233A MEP2016233A ME02515B ME 02515 B ME02515 B ME 02515B ME P2016233 A MEP2016233 A ME P2016233A ME 02515 B ME02515 B ME 02515B
Authority
ME
Montenegro
Prior art keywords
seq
ser
polypeptide
sequence
val
Prior art date
Application number
MEP-2016-233A
Other languages
German (de)
English (en)
French (fr)
Inventor
Stephanie Marie Eaton Truhlar
Neungseon Seo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49918813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02515(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ME02515B publication Critical patent/ME02515B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

 
SPISAK SLJEDOVA
 
 
<110> Eli Lily and Company
 
<120> Protutijela protiv BMP-6
 
<130> X19829
 
<150> 61/737,859
<151> 2012-12-17
 
<160> 17
 
<170> PatentIn verzija 3.5
 
 
<210> 1
<211> 490
<212> PRT
<213> Homo sapiens
 
<400> 1
 
Pro Pro Pro Leu Arg Pro Pro Leu Pro Ala Ala Ala Ala Ala Ala Ala
1 5 10 15
 
 
Gly Gly Gln Leu Leu Gly Asp Gly Gly Ser Pro Gly Arg Thr Glu Gln
20 25 30
 
 
Pro Pro Pro Ser Pro Gln Ser Ser Ser Gly Phe Leu Tyr Arg Arg Leu
35 40 45
 
 
Lys Thr Gln Glu Lys Arg Glu Met Gln Lys Glu Ile Leu Ser Val Leu
50 55 60
 
 
Gly Leu Pro His Arg Pro Arg Pro Leu His Gly Leu Gln Gln Pro Gln
65 70 75 80
 
 
Pro Pro Ala Leu Arg Gln Gln Glu Glu Gln Gln Gln Gln Gln Gln Leu
85 90 95
 
 
Pro Arg Gly Glu Pro Pro Pro Gly Arg Leu Lys Ser Ala Pro Leu Phe
100 105 110
 
 
Met Leu Asp Leu Tyr Asn Ala Leu Ser Ala Asp Asn Asp Glu Asp Gly
115 120 125
 
 
Ala Ser Glu Gly Glu Arg Gln Gln Ser Trp Pro His Glu Ala Ala Ser
130 135 140
 
 
Ser Ser Gln Arg Arg Gln Pro Pro Pro Gly Ala Ala His Pro Leu Asn
145 150 155 160
 
 
Arg Lys Ser Leu Leu Ala Pro Gly Ser Gly Ser Gly Gly Ala Ser Pro
165 170 175
 
 
Leu Thr Ser Ala Gln Asp Ser Ala Phe Leu Asn Asp Ala Asp Met Val
180 185 190
 
 
Met Ser Phe Val Asn Leu Val Glu Tyr Asp Lys Glu Phe Ser Pro Arg
195 200 205
 
 
Gln Arg His His Lys Glu Phe Lys Phe Asn Leu Ser Gln Ile Pro Glu
210 215 220
 
 
Gly Glu Val Val Thr Ala Ala Glu Phe Arg Ile Tyr Lys Asp Cys Val
225 230 235 240
 
 
Met Gly Ser Phe Lys Asn Gln Thr Phe Leu Ile Ser Ile Tyr Gln Val
245 250 255
 
 
Leu Gln Glu His Gln His Arg Asp Ser Asp Leu Phe Leu Leu Asp Thr
260 265 270
 
 
Arg Val Val Trp Ala Ser Glu Glu Gly Trp Leu Glu Phe Asp Ile Thr
275 280 285
 
 
Ala Thr Ser Asn Leu Trp Val Val Thr Pro Gln His Asn Met Gly Leu
290 295 300
 
 
Gln Leu Ser Val Val Thr Arg Asp Gly Val His Val His Pro Arg Ala
305 310 315 320
 
 
Ala Gly Leu Val Gly Arg Asp Gly Pro Tyr Asp Lys Gln Pro Phe Met
325 330 335
 
 
Val Ala Phe Phe Lys Val Ser Glu Val His Val Arg Thr Thr Arg Ser
340 345 350
 
 
Ala Ser Ser Arg Arg Arg Gln Gln Ser Arg Asn Arg Ser Thr Gln Ser
355 360 365
 
 
Gln Asp Val Ala Arg Val Ser Ser Ala Ser Asp Tyr Asn Ser Ser Glu
370 375 380
 
 
Leu Lys Thr Ala Cys Arg Lys His Glu Leu Tyr Val Ser Phe Gln Asp
385 390 395 400
 
 
Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Lys Gly Tyr Ala Ala Asn
405 410 415
 
 
Tyr Cys Asp Gly Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala
420 425 430
 
 
Thr Asn His Ala Ile Val Gln Thr Leu Val His Leu Met Asn Pro Glu
435 440 445
 
 
Tyr Val Pro Lys Pro Cys Cys Ala Pro Thr Lys Leu Asn Ala Ile Ser
450 455 460
 
 
Val Leu Tyr Phe Asp Asp Asn Ser Asn Val Ile Leu Lys Lys Tyr Arg
465 470 475 480
 
 
Asn Met Val Val Arg Ala Cys Gly Cys His
485 490
 
 
<210> 2
<211> 11
<212> PRT
<213> Umjetni slijed
 
<220>
<223> Sintetski konstrukt
 
<400> 2
 
Arg Ser Ser Glu Asn Ile Tyr Arg Asn Leu Ala
1 5 10
 
 
<210> 3
<211> 7
<212> PRT
<213> Umjetni slijed
 
<220>
<223> Sintetski konstrukt
 
<400> 3
 
Ala Ala Thr Asn Leu Ala Asp
1 5
 
 
<210> 4
<211> 9
<212> PRT
<213> Umjetni slijed
 
<220>
<223> Sintetski konstrukt
 
<400> 4
 
Gln Gly Ile Trp Gly Thr Pro Leu Thr
1 5
 
 
<210> 5
<211> 10
<212> PRT
<213> Umjetni slijed
 
<220>
<223> Sintetski konstrukt
 
<400> 5
 
Gly Tyr Thr Phe Thr Ser Tyr Ala Met His
1 5 10
 
 
<210> 6
<211> 17
<212> PRT
<213> Umjetni slijed
 
<220>
<223> Sintetski konstrukt
 
<400> 6
 
Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Asn Phe Lys
1 5 10 15
 
 
Gly
 
 
 
<210> 7
<211> 17
<212> PRT
<213> Umjetni slijed
 
<220>
<223> Sintetski konstrukt
 
<400> 7
 
Tyr Ile Asn Pro Tyr Asn Arg Gly Thr Lys Tyr Asn Glu Asn Phe Lys
1 5 10 15
 
 
Gly
 
 
 
<210> 8
<211> 9
<212> PRT
<213> Umjetni slijed
 
<220>
<223> Sintetski konstrukt
 
<400> 8
 
Arg Pro Phe Gly Asn Ala Met Asp Ile
1 5
 
 
<210> 9
<211> 107
<212> PRT
<213> Umjetni slijed
 
<220>
<223> Sintetski konstrukt
 
<400> 9
 
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
 
 
Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Glu Asn Ile Tyr Arg Asn
20 25 30
 
 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
 
 
Tyr Ala Ala Thr Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
 
 
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
 
 
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Ile Trp Gly Thr Pro Leu
85 90 95
 
 
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
 
 
<210> 10
<211> 118
<212> PRT
<213> Umjetni slijed
 
<220>
<223> Sintetski konstrukt
 
<400> 10
 
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
 
 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
 
 
Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
 
 
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Asn Phe
50 55 60
 
 
Lys Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
 
 
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
 
 
Ala Arg Arg Pro Phe Gly Asn Ala Met Asp Ile Trp Gly Gln Gly Thr
100 105 110
 
 
Leu Val Thr Val Ser Ser
115
 
 
<210> 11
<211> 118
<212> PRT
<213> Umjetni slijed
 
<220>
<223> Sintetski konstrukt
 
<400> 11
 
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
 
 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
 
 
Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
 
 
Gly Tyr Ile Asn Pro Tyr Asn Arg Gly Thr Lys Tyr Asn Glu Asn Phe
50 55 60
 
 
Lys Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
 
 
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
 
 
Ala Arg Arg Pro Phe Gly Asn Ala Met Asp Ile Trp Gly Gln Gly Thr
100 105 110
 
 
Leu Val Thr Val Ser Ser
115
 
 
<210> 12
<211> 214
<212> PRT
<213> Umjetni slijed
 
<220>
<223> Sintetski konstrukt
 
<400> 12
 
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
 
 
Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Glu Asn Ile Tyr Arg Asn
20 25 30
 
 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
 
 
Tyr Ala Ala Thr Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
 
 
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
 
 
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Ile Trp Gly Thr Pro Leu
85 90 95
 
 
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
 
 
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
 
 
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
 
 
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
 
 
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
 
 
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
 
 
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
 
 
Phe Asn Arg Gly Glu Cys
210
 
 
<210> 13
<211> 444
<212> PRT
<213> Umjetni slijed
 
<220>
<223> Sintetski konstrukt
 
<400> 13
 
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
 
 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
 
 
Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
 
 
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Asn Phe
50 55 60
 
 
Lys Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
 
 
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
 
 
Ala Arg Arg Pro Phe Gly Asn Ala Met Asp Ile Trp Gly Gln Gly Thr
100 105 110
 
 
Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
115 120 125
 
 
Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly
130 135 140
 
 
Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
145 150 155 160
 
 
Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
165 170 175
 
 
Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
180 185 190
 
 
Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser
195 200 205
 
 
Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys
210 215 220
 
 
Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu
225 230 235 240
 
 
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
245 250 255
 
 
Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln
260 265 270
 
 
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
275 280 285
 
 
Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu
290 295 300
 
 
Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
305 310 315 320
 
 
Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys
325 330 335
 
 
Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
340 345 350
 
 
Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
355 360 365
 
 
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
370 375 380
 
 
Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
385 390 395 400
 
 
Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln
405 410 415
 
 
Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
420 425 430
 
 
His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly
435 440
 
 
<210> 14
<211> 444
<212> PRT
<213> Umjetni slijed
 
<220>
<223> Sintetski konstrukt
 
<400> 14
 
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
 
 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
 
 
Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
 
 
Gly Tyr Ile Asn Pro Tyr Asn Arg Gly Thr Lys Tyr Asn Glu Asn Phe
50 55 60
 
 
Lys Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
 
 
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
 
 
Ala Arg Arg Pro Phe Gly Asn Ala Met Asp Ile Trp Gly Gln Gly Thr
100 105 110
 
 
Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
115 120 125
 
 
Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly
130 135 140
 
 
Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
145 150 155 160
 
 
Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
165 170 175
 
 
Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
180 185 190
 
 
Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser
195 200 205
 
 
Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys
210 215 220
 
 
Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu
225 230 235 240
 
 
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
245 250 255
 
 
Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln
260 265 270
 
 
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
275 280 285
 
 
Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu
290 295 300
 
 
Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
305 310 315 320
 
 
Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys
325 330 335
 
 
Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
340 345 350
 
 
Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
355 360 365
 
 
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
370 375 380
 
 
Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
385 390 395 400
 
 
Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln
405 410 415
 
 
Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
420 425 430
 
 
His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly
435 440
 
 
<210> 15
<211> 642
<212> DNA
<213> Umjetni slijed
 
<220>
<223> Sintetski konstrukt
 
<400> 15
 
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
 
atcacttgcc gatcttccga aaatatttac cgtaatttag catggtatca gcagaaacca 120
 
gggaaagccc ctaagctcct gatctatgct gcaacaaact tagcagatgg ggtcccatca 180
 
aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240
 
gaagattttg caacttacta ctgtcaaggc atttggggta ctccgctcac tttcggcgga 300
 
gggaccaagg tggagatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcca 360
 
tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 420
 
cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 480
 
gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 540
 
ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc 600
 
ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gc 642
 
 
<210> 16
<211> 1332
<212> DNA
<213> Umjetni slijed
 
<220>
<223> Sintetski konstrukt
 
<400> 16
 
caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60
 
tcctgcaagg cttctggata tacattcact agctatgcta tgcactgggt gcgacaggcc 120
 
cctggacaag ggcttgagtg gatgggatat attaatcctt ataatgatgg tactaagtac 180
 
aatgagaact tcaaaggcag agtcacgatt accgcggacg aatccacgag cacagcctac 240
 
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagaaggccc 300
 
tttggtaacg ctatggacat ttggggccag ggcaccctgg tcaccgtctc ctcagcctcc 360
 
accaagggcc catcggtctt cccgctagcg ccctgctcca ggagcacctc cgagagcaca 420
 
gccgccctgg gctgcctggt caaggactac ttccccgaac cggtgacggt gtcgtggaac 480
 
tcaggcgccc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc 540
 
tactccctca gcagcgtggt gaccgtgccc tccagcagct tgggcacgaa gacctacacc 600
 
tgcaacgtag atcacaagcc cagcaacacc aaggtggaca agagagttga gtccaaatat 660
 
ggtcccccat gcccaccctg cccagcacct gaggccgccg ggggaccatc agtcttcctg 720
 
ttccccccaa aacccaagga cactctcatg atctcccgga cccctgaggt cacgtgcgtg 780
 
gtggtggacg tgagccagga agaccccgag gtccagttca actggtacgt ggatggcgtg 840
 
gaggtgcata atgccaagac aaagccgcgg gaggagcagt tcaacagcac gtaccgtgtg 900
 
gtcagcgtcc tcaccgtcct gcaccaggac tggctgaacg gcaaggagta caagtgcaag 960
 
gtctccaaca aaggcctccc gtcctccatc gagaaaacca tctccaaagc caaagggcag 1020
 
ccccgagagc cacaggtgta caccctgccc ccatcccagg aggagatgac caagaaccag 1080
 
gtcagcctga cctgcctggt caaaggcttc taccccagcg acatcgccgt ggagtgggaa 1140
 
agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc 1200
 
tccttcttcc tctacagcag gctaaccgtg gacaagagca ggtggcagga ggggaatgtc 1260
 
ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacacagaa gagcctctcc 1320
 
ctgtctctgg gt 1332
 
 
<210> 17
<211> 1332
<212> DNA
<213> Umjetni slijed
 
<220>
<223> Sintetski konstrukt
 
<400> 17
 
caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60
 
tcctgcaagg cttctggata tacattcact agctatgcta tgcactgggt gcgacaggcc 120
 
cctggacaag ggcttgagtg gatgggatat attaatcctt ataatcgtgg tactaagtac 180
 
aatgagaact tcaaaggcag agtcacgatt accgcggacg aatccacgag cacagcctac 240
 
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagaaggccc 300
 
tttggtaacg ctatggacat ttggggccag ggcaccctgg tcaccgtctc ctcagcctcc 360
 
accaagggcc catcggtctt cccgctagcg ccctgctcca ggagcacctc cgagagcaca 420
 
gccgccctgg gctgcctggt caaggactac ttccccgaac cggtgacggt gtcgtggaac 480
 
tcaggcgccc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc 540
 
tactccctca gcagcgtggt gaccgtgccc tccagcagct tgggcacgaa gacctacacc 600
 
tgcaacgtag atcacaagcc cagcaacacc aaggtggaca agagagttga gtccaaatat 660
 
ggtcccccat gcccaccctg cccagcacct gaggccgccg ggggaccatc agtcttcctg 720
 
ttccccccaa aacccaagga cactctcatg atctcccgga cccctgaggt cacgtgcgtg 780
 
gtggtggacg tgagccagga agaccccgag gtccagttca actggtacgt ggatggcgtg 840
 
gaggtgcata atgccaagac aaagccgcgg gaggagcagt tcaacagcac gtaccgtgtg 900
 
gtcagcgtcc tcaccgtcct gcaccaggac tggctgaacg gcaaggagta caagtgcaag 960
 
gtctccaaca aaggcctccc gtcctccatc gagaaaacca tctccaaagc caaagggcag 1020
 
ccccgagagc cacaggtgta caccctgccc ccatcccagg aggagatgac caagaaccag 1080
 
gtcagcctga cctgcctggt caaaggcttc taccccagcg acatcgccgt ggagtgggaa 1140
 
agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc 1200
 
tccttcttcc tctacagcag gctaaccgtg gacaagagca ggtggcagga ggggaatgtc 1260
 
ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacacagaa gagcctctcc 1320
 
ctgtctctgg gt 1332
 
 

Claims (16)

1. Protutijelo, ili njegov antigenski vežući fragment, koje se veže na ljudski BMP-6 (SEQ ID NO: 1), naznačeno time što sadrži varijabilno područje lakog lanca (LCVR) i varijabilno područje teškog lanca (HCVR), gdje LCVR sadrži područja za određivanje komplementarnosti (CDR) LCDR1, LCDR2 i LCDR3, a HCVR sadrži CDR HCDR1, HCDR2 i HCDR3, gdje je LCDR1 polipeptid sa slijedom RSSENIYRNLA (SEQ ID NO: 2), LCDR2 je polipeptid sa slijedom AATNLAD (SEQ ID NO: 3), LCDR3 je polipeptid sa slijedom QGIWGTPLT (SEQ ID NO: 4), HCDR1 je polipeptid sa slijedom GYTFTSYAMH (SEQ ID NO: 5), HCDR2 je polipeptid sa slijedom YINPYNDGTKYNENFKG (SEQ ID NO: 6) ili YINPYNRGTKYNENFKG (SEQ ID NO: 7), a HCDR3 je polipeptid sa slijedom RPFGNAMDI (SEQ ID NO: 8).
2. Protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 1, naznačeno time što je LCDR1 polipeptid sa slijedom RSSENIYRNLA (SEQ ID NO: 2), LCDR2 je polipeptid sa slijedom AATNLAD (SEQ ID NO: 3), LCDR3 je polipeptid sa slijedom QGIWGTPLT (SEQ ID NO: 4), HCDR1 je polipeptid sa slijedom GYTFTSYAMH (SEQ ID NO: 5), HCDR2 je polipeptid sa slijedom YINPYNDGTKYNENFKG (SEQ ID NO: 6), a HCDR3 je polipeptid sa slijedom RPFGNAMDI (SEQ ID NO: 8).
3. Protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 1, naznačeno time što je LCDR1 polipeptid sa slijedom RSSENIYRNLA (SEQ ID NO: 2), LCDR2 je polipeptid sa slijedom AATNLAD (SEQ ID NO: 3), LCDR3 je polipeptid sa slijedom QGIWGTPLT (SEQ ID NO: 4), HCDR1 je polipeptid sa slijedom GYTFTSYAMH (SEQ ID NO: 5), HCDR2 je polipeptid sa slijedom YINPYNRGTKYNENFKG (SEQ ID NO: 7), a HCDR3 je polipeptid sa slijedom RPFGNAMDI (SEQ ID NO: 8).
4. Protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 1, naznačeno time što sadrži LCVR i HCVR, gdje je LCVR polipeptid sa slijedom SEQ ID NO: 9, a HCVR je polipeptid sa slijedom SEQ ID NO: 10 ili SEQ ID NO: 11.
5. Protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 4, naznačeno time što LCVR je polipeptid sa slijedom SEQ ID NO: 9, a HCVR je polipeptid sa slijedom SEQ ID NO: 10.
6. Protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 4, naznačeno time što LCVR je polipeptid sa slijedom SEQ ID NO: 9, a HCVR je polipeptid sa slijedom SEQ ID NO: 11.
7. Protutijelo u skladu s patentnim zahtjevom 1 ili 4, naznačeno time što sadrži laki lanac (LC) i teški lanac (HC), gdje je LC polipeptid sa slijedom SEQ ID NO: 12, a HC je polipeptid sa slijedom SEQ ID NO: 13 ili SEQ ID NO: 14.
8. Protutijelo u skladu s patentnim zahtjevom 7, naznačeno time što LC je polipeptid sa slijedom SEQ ID NO: 12, a HC je polipeptid sa slijedom SEQ ID NO: 13.
9. Protutijelo u skladu s patentnim zahtjevom 7, naznačeno time što LC je polipeptid sa slijedom SEQ ID NO: 12, a HC je polipeptid sa slijedom SEQ ID NO: 14.
10. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1, 4, ili 7, naznačeno time što sadrži dva laka lanca i dva teška lanca, gdje je svaki laki lanac polipeptid sa slijedom SEQ ID NO: 12, a svaki teški lanac je polipeptid sa slijedom SEQ ID NO: 13.
11. Protutijelo u skladu s bilo kojim od patentnim zahtjevom 1, 4, ili 7, naznačeno time što sadrži dva laka lanca i dva teška lanca, gdje je svaki laki lanac polipeptid sa slijedom SEQ ID NO: 12, a svaki teški lanac je polipeptid sa slijedom SEQ ID NO: 14.
12. Farmaceutski pripravak, naznačen time što sadrži protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1-11, kao i prihvatljiv nosač, razrjeđivač ili pomoćnu tvar.
13. Protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1-11, naznačeno time što je namijenjeno upotrebi u terapiji.
14. Protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1-11, naznačeno time što je namijenjeno upotrebi u liječenju anemije.
15. Protutijelo, ili njegov antigenski vežući fragment, namijenjeno upotrebi u skladu s patentnim zahtjevom 14, naznačeno time što je anemija anemija kod kronične bolesti.
16. Protutijelo, ili njegov antigenski vežući fragment, namijenjeno upotrebi u skladu s patentnim zahtjevom 15, naznačeno time što se anemija kod kronične bolesti bira iz skupine koju čine anemija kod raka i anemija kod kronične bolesti bubrega.
MEP-2016-233A 2012-12-17 2013-12-05 Protutijela protiv bmp-6 ME02515B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737859P 2012-12-17 2012-12-17
EP13818045.0A EP2931748B1 (en) 2012-12-17 2013-12-05 Bmp-6 antibodies
PCT/US2013/073239 WO2014099391A1 (en) 2012-12-17 2013-12-05 Bmp-6 antibodies

Publications (1)

Publication Number Publication Date
ME02515B true ME02515B (me) 2017-02-20

Family

ID=49918813

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-233A ME02515B (me) 2012-12-17 2013-12-05 Protutijela protiv bmp-6

Country Status (33)

Country Link
US (2) US8795665B2 (me)
EP (1) EP2931748B1 (me)
JP (1) JP6033459B2 (me)
KR (1) KR20150083918A (me)
CN (1) CN104870473B (me)
AP (1) AP2015008600A0 (me)
AR (1) AR093620A1 (me)
AU (1) AU2013363548A1 (me)
BR (1) BR112015012708A2 (me)
CA (1) CA2892911C (me)
CL (1) CL2015001639A1 (me)
CY (1) CY1118254T1 (me)
DK (1) DK2931748T3 (me)
EA (1) EA201590918A1 (me)
ES (1) ES2608381T3 (me)
HR (1) HRP20161587T1 (me)
HU (1) HUE032431T2 (me)
IL (1) IL239242A0 (me)
LT (1) LT2931748T (me)
MA (1) MA38161A1 (me)
ME (1) ME02515B (me)
MX (1) MX2015007831A (me)
PE (1) PE20151164A1 (me)
PH (1) PH12015501360A1 (me)
PL (1) PL2931748T3 (me)
PT (1) PT2931748T (me)
RS (1) RS55413B1 (me)
SG (1) SG11201504695QA (me)
SI (1) SI2931748T1 (me)
TN (1) TN2015000277A1 (me)
TW (1) TW201439118A (me)
WO (1) WO2014099391A1 (me)
ZA (1) ZA201504282B (me)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR093620A1 (es) 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
GB2550114A (en) 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists
US11434269B2 (en) 2016-06-15 2022-09-06 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
GB201815629D0 (en) * 2018-09-25 2018-11-07 Kymab Ltd Antagonists
US20220251184A1 (en) * 2019-06-12 2022-08-11 Regeneron Pharmaceuticals, Inc. Human antibodies to bone morphogenetic protein 6
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
CA3174339A1 (en) * 2020-04-07 2021-10-14 Xin Du Anti-tmprss6 antibodies and uses thereof
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN114075287B (zh) * 2020-08-18 2023-07-21 湖南远泰生物技术有限公司 人源化bcma抗体和bcma-car-t细胞

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077006A1 (en) 2001-03-23 2002-10-03 Human Genome Sciences, Inc. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
EP2335719B1 (en) 2005-02-16 2015-06-24 The General Hospital Corporation Use of hemojuvelin fusion proteins to regulate hepcidin-mediated iron metabolism
WO2010056981A2 (en) * 2008-11-13 2010-05-20 Massachusetts General Hospital Methods and compositions for regulating iron homeostasis by modulation bmp-6
US20110070242A1 (en) * 2009-09-01 2011-03-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for Diagnosing and Treating Iron Dysregulation
AR093620A1 (es) 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6

Also Published As

Publication number Publication date
EP2931748B1 (en) 2016-10-05
JP6033459B2 (ja) 2016-11-30
SG11201504695QA (en) 2015-07-30
CY1118254T1 (el) 2017-06-28
MX2015007831A (es) 2015-08-20
WO2014099391A1 (en) 2014-06-26
CA2892911A1 (en) 2014-06-26
ZA201504282B (en) 2017-11-29
AP2015008600A0 (en) 2015-07-31
HRP20161587T1 (hr) 2017-01-13
US8980582B2 (en) 2015-03-17
RS55413B1 (sr) 2017-04-28
US20140170161A1 (en) 2014-06-19
MA38161A1 (fr) 2017-12-29
ES2608381T3 (es) 2017-04-10
HK1209763A1 (en) 2016-04-08
IL239242A0 (en) 2015-07-30
SI2931748T1 (sl) 2017-01-31
PH12015501360A1 (en) 2015-09-02
CN104870473B (zh) 2018-05-29
CL2015001639A1 (es) 2015-10-02
KR20150083918A (ko) 2015-07-20
EA201590918A1 (ru) 2015-10-30
HUE032431T2 (en) 2017-09-28
DK2931748T3 (da) 2017-01-02
US8795665B2 (en) 2014-08-05
EP2931748A1 (en) 2015-10-21
CA2892911C (en) 2017-02-28
PE20151164A1 (es) 2015-08-19
JP2016501273A (ja) 2016-01-18
BR112015012708A2 (pt) 2017-09-12
TN2015000277A1 (en) 2016-10-03
US20140309404A1 (en) 2014-10-16
TW201439118A (zh) 2014-10-16
CN104870473A (zh) 2015-08-26
PL2931748T3 (pl) 2017-05-31
AU2013363548A1 (en) 2015-05-28
PT2931748T (pt) 2016-11-02
AR093620A1 (es) 2015-06-10
LT2931748T (lt) 2017-01-10

Similar Documents

Publication Publication Date Title
ME02515B (me) Protutijela protiv bmp-6
US10280207B2 (en) FcRn-specific human antibody and composition for treatment of autoimmune diseases
KR102141969B1 (ko) 항-N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도
JP7755634B2 (ja) アクチビン2型受容体結合タンパク質及びその使用
KR101859911B1 (ko) 사람 gdf8에 대한 항체
KR20100018499A (ko) 항ⅠgE 항체
TW201043638A (en) Compositions and methods for antibodies targeting complement protein C3b
WO2018161872A1 (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
KR20130051989A (ko) 항―N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도
CN114786776A (zh) 针对ceacam5和cd3的双特异性抗体
CN101809035A (zh) 能结合胸腺基质淋巴细胞生成素的抗原结合蛋白
JP2015503909A5 (me)
US20240301041A1 (en) Anti-staphylococcus antibodies and uses thereof
CN108026167B (zh) 特异性结合分离的衍生自波形蛋白的肽的抗体或该肽的结合片段
RU2019103991A (ru) Анти-il-22r-антитела
CN111148529A (zh) 用于预防和治疗皮肤疾病的包含特异性结合波形蛋白衍生肽的物质的组合物
KR101943724B1 (ko) Ang2 항체
JP2018531625A5 (me)
CN113956352B (zh) 新型冠状病毒中和性抗体及其制备方法与用途
CN111333724B (zh) 一种抗金黄色葡萄球菌肠毒素b的单克隆抗体yg11-1及其应用
CN106795218A (zh) VEGFR2/Ang2化合物
HK40076068A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
HK40075893A (en) Bispecific antibodies against ceacam5 and cd3
HK40002449B (en) Activin type 2 receptor binding proteins and uses thereof
HK40002449A (en) Activin type 2 receptor binding proteins and uses thereof